|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | HER2阳性乳腺癌的治疗策略显示文摘目前乳腺癌的治疗方法逐渐发展为根据肿瘤特征〔如人表皮生长因子受体(HER)2的过表达〕而进行的个体化治疗。随着曲妥珠单抗的出现,在各种治疗方案中,患者的预后都得到了改善。全新的治疗方法,如拉帕替尼已经获得了美国FDA的批准。此外,人源化的单克隆抗体帕妥珠单抗,已经进入Ⅱ期和Ⅲ期临床试验。 | Engel RH Kaklammi VG 李冬梅 吕娟丽 何慧丽 | 2008 | 国际药学研究杂志2008，35，4： | 3 |
| 2 | HER2 - positive breast cancer: Current and future treatment strategies 显示文摘 | Engel RH Kaklamani VG | 2007 | Drugs2007，67，9： | 1 |
| 3 | The use of dabigatran immediately after atrial fibrillation ablation显示文摘 | Winkle RA Mead RH Engel G | 2012 | J Cardiovasc Electrophysiol2012，23，3： | 1 |
| 4 | HER2 -positive breast cancer: cur- rent and future treatment strategies 显示文摘 | Engel RH Kaklamani VG | 2007 | Drugs2007，67，9： | 1 |
| 5 | Oxidative stress and apoptosis: a new treat- ment paradigm in cancer显示文摘 | Engel RH Evens AM | 2006 | Front Biosci2006，，11： | 1 |
| 6 | HER2-positive breast cancer: current and future treatment strategies显示文摘 | Engel RH Kaklamani VG | 2007 | Drugs2007，67，9： | 1 |
| 7 | HER2 -positive breast cancer:current and future treatment strategies 显示文摘 | Engel RH Kaklamani VG | 2007 | Drugs2007，67，9： | 1 |
| 8 | The use of dabigatran immediately after atrial fibrillation ablation 显示文摘 | Winkle RA Mead RH Engel G | 2012 | J Cardiovasc Electrophysiol2012，23，3： | 1 |
| 9 | The use of dabigatran immediately af- ter atrial fibrillation ablation显示文摘 | Winkle RA Mead RH Engel G et at | 2012 | J Cardiovasc Electrophysiol2012，23，： | 1 |
| 10 | Oxidative stress and apoptosis: a new treatment paradigm in cancer 显示文摘 | Engel RH Evens AM | 2006 | Front Biosci2006，11，1： | 1 |
| 11 | Discontinuing anticoagnlation following successful atrial fibrillation ablation patients with prior strokes显示文摘 | Winkle RA Mead RH Engel G | 2013 | ] Interv Card Electrophysiol2013，38，3： | 1 |
| 12 | Safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing ablation for atrial fibrillation显示文摘 | Winkle RA Mead RH Engel G | 2012 | J Am Coll Cardiol2012，60，12： | 1 |
| 13 | The use of dabigatran immediately after atrial fibrillation ablation 显示文摘 | Winkle RA Mead RH Engel G | 2012 | J Cardiovasc Electrophysiol2012，23，3： | 1 |
| 14 | The use of dabigatran immediately after atrial fibrillation ablation 显示文摘 | Winkle RA Mead RH Engel G | 2012 | J Cardiovac Elec- trophysiol2012，23，3： | 1 |
| 15 | Safety of lower activat- ed clotting times during atrial fibrillation ablation using open irrigated tip catheters and a single transseptal puncture显示文摘 | Winkle RA Mead RH Engel G | 2011 | Am J Cardiol2011，107，5： | 1 |
| 16 | The use of dabigatran immediately after atrial fibrillation ablation显示文摘 | WINKLE RA MEAD RH ENGEL G | 2012 | J Cardiovasc Electrophysiol2012，23，3： | 1 |
| 17 | The use of dabigatran immediately after atrial fibrillation ablation 显示文摘 | Winkle RA Mead RH Engel G | 2012 | J Cardiovasc Electrephysiol2012，23，3： | 1 |
| 18 | HER2-positive breast cancer: current and future treatment strategies显示文摘 | Engel RH Kaklamani VG | 2007 | Drugs2007，67，9： | 1 |
| 19 | Peri-procedural inter- rupted oral anticoagulation for atrial fibrillation ablation com- parison of aspirin, warfarin, dabigatran, and rivaroxaban显示文摘 | Winkle RA Mead RH Engel G | 2014 | Europaee2014，16，： | 1 |
| 20 | Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation : comparison of aspirin, warfarin, dabigatran,and rivaroxaban显示文摘 | Winkle RA Mead RH Engel G | 2014 | Europace2014，16，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员